NCT03877003 is a NA clinical trial of Eggs in Coronary Artery Disease, sponsored by University of Connecticut.

Who is sponsoring NCT03877003?

NCT03877003 is sponsored by University of Connecticut.

What drugs are being tested in NCT03877003?

Interventions in NCT03877003: Eggs.

What condition does NCT03877003 study?

NCT03877003 studies Coronary Artery Disease, Diabetes, Metabolic Syndrome.

Is NCT03877003 still recruiting?

NCT03877003 is currently completed. Last updated 3 November 2020.

Last reviewed 2020-11-03 · How we verify

NCT03877003

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Plasma TMAO and Choline Levels in Individuals With Metabolic Syndrome - Comparison Between Eggs and Choline Supplement.

Completed NA Last updated 3 November 2020

What this trial tests

NA trial testing Eggs in Coronary Artery Disease in 25 participants. Completed in 30 June 2020.

Timeline

1 November 2018

Primary endpoint
14 December 2019

30 June 2020

Quick facts

Lead sponsor	University of Connecticut
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	prevention
Enrollment	25
Start date	1 November 2018
Primary completion	14 December 2019
Estimated completion	30 June 2020
Sites	2 locations across United States

Drugs / interventions tested

Eggs

Conditions studied

Coronary Artery Disease — all drugs for Coronary Artery Disease →
Diabetes — all drugs for Diabetes →
Metabolic Syndrome — all drugs for Metabolic Syndrome →

Sponsor

University of Connecticut

Who can join

Adults 35 to 70, any sex, with Coronary Artery Disease or Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The objective of this study is to determine the effects of consuming either 3 eggs per day and compare it to daily choline supplement (choline bitartrate) for a dose of approximately 400 mg/day on plasma concentrations of high density lipoprotein cholesterol (HDL-c), trimethylamine N oxide (TMAO) and plasma choline. The goal is to determine if choline given as phosphatidyl choline (from eggs) will have a more beneficial effect on plasma choline and microbiota.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Choline supplements: An update.
Kansakar U, Trimarco V, Mone P, Varzideh F, et al · · 2023 · cited 55× · PMID 36950691 · DOI 10.3389/fendo.2023.1148166
Choline Intake as Supplement or as a Component of Eggs Increases Plasma Choline and Reduces Interleukin-6 without Modifying Plasma Cholesterol in Participants with Metabolic Syndrome.
DiBella M, Thomas MS, Alyousef H, Millar C, et al · · 2020 · cited 25× · PMID 33066009 · DOI 10.3390/nu12103120
Human gut microbiome: Therapeutic opportunities for metabolic syndrome-Hype or hope?
Horvath A, Zukauskaite K, Hazia O, Balazs I, et al · · 2024 · cited 15× · PMID 37771199 · DOI 10.1002/edm2.436
Comparison between Egg Intake versus Choline Supplementation on Gut Microbiota and Plasma Carotenoids in Subjects with Metabolic Syndrome.
Thomas MS, DiBella M, Blesso CN, Malysheva O, et al · · 2022 · cited 14× · PMID 35334836 · DOI 10.3390/nu14061179
Choline in immunity: a key regulator of immune cell activation and function.
Maia C, Fung CW, Sanchez-Lopez E. · · 2025 · cited 2× · PMID 40821837 · DOI 10.3389/fimmu.2025.1617077

Verify or expand the search:

Other trials of Eggs

Trials testing the same drug.

NCT05168085 — Efficacy of Providing Eggs as an Early Complementary Food to Promote Child Growth · NA · unknown
NCT04583657 — Intestinal Tolerance & Health Effects of Daily Consumption of Two Eggs With Fatty Acid Profile Related to Metabolic Diso · NA · completed
NCT03385252 — The Mazira Project: An Evaluation of Eggs During Complementary Feeding in Rural Malawi · NA · completed
NCT02531958 — Assessment of Optimal Egg Intake in a Healthy Population · NA · completed

Other recruiting trials for Coronary Artery Disease

Currently open trials in the same condition.

NCT07399002 — LONG NAGOMI™ PMCF STUDY · recruiting
NCT07420582 — Antegrade Autologous Blood Reinfusion After CPB · recruiting
NCT07493603 — A Study on Yiyang Huoluo Decoction in the Treatment of Coronary Heart Disease · Phase 1, PHASE2 · recruiting
NCT06535568 — Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO · NA · recruiting
NCT07286578 — A Prospective, Multicenter, Randomized Controlled Trial to Investigate the Value of Coronary CT Angiography in the Under · NA · recruiting

Other University of Connecticut trials

Trials by the same sponsor.

NCT06794840 — JomCare Study - A Harm Reduction Study · NA · not yet recruiting
NCT07238556 — A Novel Digital Tool Physicians Can Use to Prescribe Exercise to Patients With Cardiovascular Disease Risk Factors · NA · recruiting
NCT06381921 — Objective Integrated Multimodal Electrophysiological Index for the Quantification of Visceral Pain · NA · recruiting
NCT06393725 — Synchronous vs Asynchronous Remotely Delivered Lifestyle Interventions · NA · recruiting
NCT04989309 — Left and Right Hemisphere Contributions to Speech Perception · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03877003 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Connecticut
Last refreshed: 3 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03877003.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing